Carisma Therapeutics Inc. (NASDAQ:CARM) Receives Average Rating of “Hold” from Analysts

Shares of Carisma Therapeutics Inc. (NASDAQ:CARM) have been assigned an average recommendation of “Hold” from the seven ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $0.90.

Several equities research analysts recently weighed in on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $1.00 price objective on shares of Carisma Therapeutics in a research report on Friday, August 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Carisma Therapeutics in a research report on Wednesday, October 8th.

Carisma Therapeutics Price Performance

Carisma Therapeutics stock opened at $0.05 on Thursday. The firm has a market cap of $1.88 million, a PE ratio of 0.06 and a beta of 1.94. The stock’s fifty day moving average price is $0.12 and its two-hundred day moving average price is $0.26. Carisma Therapeutics has a one year low of $0.03 and a one year high of $1.27.

Carisma Therapeutics (NASDAQ:CARM) last released its earnings results on Wednesday, November 12th. The company reported $1.07 earnings per share for the quarter. The company had revenue of $45.25 million for the quarter. Sell-side analysts expect that Carisma Therapeutics will post -1.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Carisma Therapeutics news, insider Michael Klichinsky sold 200,000 shares of the business’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $0.25, for a total transaction of $50,000.00. Following the completion of the transaction, the insider directly owned 119,347 shares in the company, valued at $29,836.75. The trade was a 62.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 541,329 shares of company stock worth $138,176 in the last three months. 6.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Carisma Therapeutics

A hedge fund recently bought a new stake in Carisma Therapeutics stock. Jane Street Group LLC acquired a new position in shares of Carisma Therapeutics Inc. (NASDAQ:CARM) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 150,810 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 0.36% of Carisma Therapeutics at the end of the most recent reporting period. Institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.